Public procurement notice: Contract Award Notice
Published: 2024-06-05
Buyer: SYKEHUSINNKJØP HF
Country: NO
Region: NO074
Contract type: Supplies
Procedure: Negotiated without a prior call for competition
CPV classification: 33600000: Pharmaceutical products
Estimated value: 4000000 NOK
Submission deadline: 2027-01-30
Award criteria: price

Technical requirements: After the competition, tenders have been submitted for the medicine 414022 Peyona, with a medicine form such as infusion fluid and mixing solution (solution), where the tenderer has marketing authorisation. See the Medicines Act § 8 and the medicines regulations § 2-1 first and second paragraphs, where, as a main rule, there are requirements for marketing permits before the turnover of medicines can occur. No other suppliers have marketing authorisation for the active ingredient Caffeine N06BC01 with this medicine form. Based on this, Sykehusinnkjøp HF, division of medicines, intends to enter into agreements between the regional health companies (contracting authorities) and Chiesi Pharma AB as an additional contract for 2501c Inf inj pharmaceuticals, i.e. the extent and duration of the contract shall follow the mentioned procurement (including access to prolongation and termination), without a new competition being announced for this active ingredient. The health authorities that are subject to the regional health authorities have an option to join the agreement. The same applies to ideal institutions/hospitals with operational agreements with each health region. Sykehusinnkjøp HF has examined the market situation and estimates that it is not possible to have a new competition or that a supplier other than Chiesi Pharma AB can deliver the product in the pending contract period. Sykehusinnkjøp HF therefore believes that it is necessary to implement the procurement without a competition. See the procurement regulations §21-5, cf. § 21-2, cf. § 13-4 letter b no. 3 and letter cf. also §13-3 letter e.Sykehusinnkjøp HF, division medicines ask those who possibly have objections to this intention of giving feedback by the end of the waiting period, which is set for 19.06.2024. If objections are not received, contracts will be signed after the waiting period has expired.
Sykehusinnkjøp HF, division pharmaceuticals, is collecting tenders for medicines that are used by the health authorities. We have previously announced and implemented an open tender contest for 2501c Inf inj pharmaceuticals. The competition included active substances in accordance with the tender documentation annex 03 Price Form.
At the end of the Contract period, the Contracting Authority can extend all or parts of the Contract for up to 1 year if 
Time. The total maximum agreement period is 4 years. 
The contracting authority has a unilateral right to extend all or parts of the Agreement on the 
original terms. The tenderer cannot oppose such an extension.
The Contracting Authority, c/o the Contract Manager, shall, in writing and at the latest two months before the Contract expires, notify the Tenderer. 
for an extension of the Agreement. This does not prevent the Tenderer from being able, upon request, to 
accept a shorter deadline for notice on extension of the Agreement.


Number of bids: 1